Sarge, I disagree, if the company is looking to maximise impact and profits, then Australia should be the last region it seeks approvals for.
@Joelsmith2452 .... we are in the middle of a once in a one hundred year pandemic; multiple submissions should be lodged simultaneously in multiple regions IMO ... no one knows where or when an outbreak will occur ... one of the main reasons I wanted a large pharma deal to handle things like multiple regulatory submissions - we simply don’t have the resources
Viraleze marketing, page-89
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $45.99M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 12.0¢ | 10.5¢ | $114.6K | 998.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 171158 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 204 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |